Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-08-09

AUTHORS

Shaheenah Dawood, Maria Konstantionva, Rebecca Dent, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Franco, Ming-Shen Dai, Sergio Simon

ABSTRACT

PurposeThe therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR + HER2 − mBC.DesignA panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR + HER2 − mBC.ResultsEvidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR + HER2 − mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR + HER2 − mBC.ConclusionThe current article will serve as a comprehensive guide for optimizing the management of HR + HER2 − mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR + HER2 − mBC. More... »

PAGES

15

References to SciGraph publications

  • 2020-05-13. Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials in BMC CANCER
  • 2019-01-17. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer in NPJ BREAST CANCER
  • 2013-12-21. Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-10-25. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis in ADVANCES IN THERAPY
  • 2018-02-15. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON) in BREAST CANCER
  • 2017-11-21. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-06-11. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2017-10-22. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-12-18. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy in NPJ BREAST CANCER
  • 2019-01-10. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-12-25. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis in BREAST CANCER
  • 2018-07-04. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis in BREAST CANCER RESEARCH AND TREATMENT
  • 2019-05-09. Recent advances in triple negative breast cancer: the immunotherapy era in BMC MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5

    DOI

    http://dx.doi.org/10.1186/s12919-021-00224-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1140286771

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34372853


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE", 
              "id": "http://www.grid.ac/institutes/grid.459770.8", 
              "name": [
                "Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dawood", 
            "givenName": "Shaheenah", 
            "id": "sg:person.0771637610.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771637610.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia", 
              "id": "http://www.grid.ac/institutes/grid.467082.f", 
              "name": [
                "Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Konstantionva", 
            "givenName": "Maria", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore", 
              "id": "http://www.grid.ac/institutes/grid.410724.4", 
              "name": [
                "Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dent", 
            "givenName": "Rebecca", 
            "id": "sg:person.01361171050.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361171050.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Centro de Educaci\u00f3n M\u00e9dicae Investigaciones Cl\u00ednicas (CEMIC), Ciudad de Buenos Aires, Argentina", 
              "id": "http://www.grid.ac/institutes/grid.418248.3", 
              "name": [
                "Department of Oncology, Centro de Educaci\u00f3n M\u00e9dicae Investigaciones Cl\u00ednicas (CEMIC), Ciudad de Buenos Aires, Argentina"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Perazzo", 
            "givenName": "Florencia", 
            "id": "sg:person.01057754421.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057754421.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea", 
              "id": "http://www.grid.ac/institutes/grid.413967.e", 
              "name": [
                "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kim", 
            "givenName": "Sung-Bae", 
            "id": "sg:person.015757640033.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015757640033.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico", 
              "id": "http://www.grid.ac/institutes/grid.419167.c", 
              "name": [
                "Centro de Cancer de Mama, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garc\u00eda, NL, Mexico", 
                "Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Villarreal-Garza", 
            "givenName": "Cynthia", 
            "id": "sg:person.01057225306.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057225306.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Head of Oncology, Cl\u00ednica del Country, Bogot\u00e1, Colombia", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Head of Oncology, Cl\u00ednica del Country, Bogot\u00e1, Colombia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Franco", 
            "givenName": "Sandra", 
            "id": "sg:person.010052147233.95", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010052147233.95"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan", 
              "id": "http://www.grid.ac/institutes/grid.278244.f", 
              "name": [
                "Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dai", 
            "givenName": "Ming-Shen", 
            "id": "sg:person.0751031116.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751031116.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Simon", 
            "givenName": "Sergio", 
            "id": "sg:person.014520232162.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014520232162.61"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s10549-018-05125-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111320245", 
              "https://doi.org/10.1007/s10549-018-05125-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12282-018-0838-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101057009", 
              "https://doi.org/10.1007/s12282-018-0838-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12885-020-06933-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127579844", 
              "https://doi.org/10.1186/s12885-020-06933-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41523-018-0094-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1110537179", 
              "https://doi.org/10.1038/s41523-018-0094-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12325-013-0060-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016141409", 
              "https://doi.org/10.1007/s12325-013-0060-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41523-018-0097-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1111375485", 
              "https://doi.org/10.1038/s41523-018-0097-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12916-019-1326-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1114002245", 
              "https://doi.org/10.1186/s12916-019-1326-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-018-0620-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1104512198", 
              "https://doi.org/10.1186/s13045-018-0620-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-018-4867-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1105296572", 
              "https://doi.org/10.1007/s10549-018-4867-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12282-012-0430-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032224793", 
              "https://doi.org/10.1007/s12282-012-0430-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-017-4523-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092334133", 
              "https://doi.org/10.1007/s10549-017-4523-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-017-4518-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092841000", 
              "https://doi.org/10.1007/s10549-017-4518-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-013-2814-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041934981", 
              "https://doi.org/10.1007/s10549-013-2814-5"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-08-09", 
        "datePublishedReg": "2021-08-09", 
        "description": "PurposeThe therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.DesignA panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.ResultsEvidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR\u2009+\u2009HER2\u2009\u2212\u2009mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.ConclusionThe current article will serve as a comprehensive guide for optimizing the management of HR\u2009+\u2009HER2\u2009\u2212\u2009mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR\u2009+\u2009HER2\u2009\u2212\u2009mBC.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12919-021-00224-5", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1039047", 
            "issn": [
              "1753-6561"
            ], 
            "name": "BMC Proceedings", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "Suppl 10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "15"
          }
        ], 
        "keywords": [
          "metastatic breast cancer", 
          "Breast Cancer Registry", 
          "treatment selection", 
          "Cancer Registry", 
          "clinical questions", 
          "cyclin-dependent kinase 4/6 inhibitors", 
          "human epidermal growth factor receptor", 
          "ovarian function suppression", 
          "optimal maintenance regimen", 
          "first-line standard", 
          "second-line treatment", 
          "initial treatment choice", 
          "key clinical questions", 
          "epidermal growth factor receptor", 
          "evidence-based answers", 
          "growth factor receptor", 
          "visceral crisis", 
          "advanced breast", 
          "endocrine therapy", 
          "oligometastatic disease", 
          "maintenance regimen", 
          "endocrine resistance", 
          "optimized care", 
          "HR positive", 
          "treatment choice", 
          "aromatase inhibitors", 
          "therapy choice", 
          "breast cancer", 
          "management of HR", 
          "unmet need", 
          "HER2", 
          "therapeutic landscape", 
          "factor receptor", 
          "key opinion leaders", 
          "registry", 
          "hr", 
          "expert group meeting", 
          "care", 
          "treatment", 
          "inhibitors", 
          "group meetings", 
          "management", 
          "regimen", 
          "patients", 
          "therapy", 
          "cancer", 
          "clinicians", 
          "breast", 
          "ResultsEvidence", 
          "disease", 
          "hormone", 
          "receptors", 
          "opinion leaders", 
          "sequencing", 
          "review", 
          "panel", 
          "current article", 
          "suppression", 
          "agents", 
          "factors", 
          "comprehensive guide", 
          "role", 
          "South Korea", 
          "choice", 
          "resistance", 
          "Taiwan", 
          "meeting", 
          "need", 
          "combination", 
          "selection", 
          "purpose", 
          "partners", 
          "literature", 
          "access", 
          "questions", 
          "guide", 
          "standards", 
          "Singapore", 
          "Korea", 
          "Brazil", 
          "answers", 
          "introduction", 
          "decisions", 
          "Colombia", 
          "UAE", 
          "article", 
          "influence", 
          "Mexico", 
          "crisis", 
          "Argentina", 
          "policy", 
          "leaders", 
          "Moscow", 
          "scenarios", 
          "landscape", 
          "sequencing decisions", 
          "algorithm", 
          "regional policy"
        ], 
        "name": "Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer \u2013 Proceedings from breast cancer expert group meeting", 
        "pagination": "15", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1140286771"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12919-021-00224-5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34372853"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12919-021-00224-5", 
          "https://app.dimensions.ai/details/publication/pub.1140286771"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-06-01T22:25", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_923.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12919-021-00224-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12919-021-00224-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    290 TRIPLES      22 PREDICATES      136 URIs      115 LITERALS      7 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12919-021-00224-5 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N8120ca377cd447d6b22d9f6db7939f43
    4 schema:citation sg:pub.10.1007/s10549-013-2814-5
    5 sg:pub.10.1007/s10549-017-4518-8
    6 sg:pub.10.1007/s10549-017-4523-y
    7 sg:pub.10.1007/s10549-018-05125-4
    8 sg:pub.10.1007/s10549-018-4867-y
    9 sg:pub.10.1007/s12282-012-0430-6
    10 sg:pub.10.1007/s12282-018-0838-8
    11 sg:pub.10.1007/s12325-013-0060-1
    12 sg:pub.10.1038/s41523-018-0094-2
    13 sg:pub.10.1038/s41523-018-0097-z
    14 sg:pub.10.1186/s12885-020-06933-y
    15 sg:pub.10.1186/s12916-019-1326-5
    16 sg:pub.10.1186/s13045-018-0620-6
    17 schema:datePublished 2021-08-09
    18 schema:datePublishedReg 2021-08-09
    19 schema:description PurposeThe therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this scenario, optimizing treatment selection and sequencing is daunting for clinicians. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection and sequencing for the management of HR + HER2 − mBC.DesignA panel of nine key opinion leaders from Argentina, Brazil, Colombia, Mexico, Moscow, Singapore, South Korea, Taiwan, and UAE convened in October 2018. They reviewed the literature and formulated answers to clinical questions on optimizing the management of HR + HER2 − mBC.ResultsEvidence-based answers were formulated for: (1) optimal initial treatment choice; (2) ovarian function suppression, optimal endocrine partner, and role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (in premenopausal women); (3) better first-line standard of care than aromatase inhibitors; (4) preferred second-line treatment; (5) treatment of oligometastatic disease; (6) factors influencing first-line single-agent endocrine therapy choice; (7) influence of endocrine resistance on treatment selection; (8) optimal maintenance regimen in visceral crisis; and (9) need for a breast cancer registry for patients with HR + HER2 − mBC. The panel also proposed a treatment-sequencing algorithm for the management of HR + HER2 − mBC.ConclusionThe current article will serve as a comprehensive guide for optimizing the management of HR + HER2 − mBC. The proposed breast cancer registry will help identify unmet needs and develop strategic regional policies to help improve access to optimized care for HR + HER2 − mBC.
    20 schema:genre article
    21 schema:inLanguage en
    22 schema:isAccessibleForFree true
    23 schema:isPartOf N0e96d729f3244b959eb25c41ffce7bab
    24 Nb58e4c7906a84796bbe7f63b2bb8dcc0
    25 sg:journal.1039047
    26 schema:keywords Argentina
    27 Brazil
    28 Breast Cancer Registry
    29 Cancer Registry
    30 Colombia
    31 HER2
    32 HR positive
    33 Korea
    34 Mexico
    35 Moscow
    36 ResultsEvidence
    37 Singapore
    38 South Korea
    39 Taiwan
    40 UAE
    41 access
    42 advanced breast
    43 agents
    44 algorithm
    45 answers
    46 aromatase inhibitors
    47 article
    48 breast
    49 breast cancer
    50 cancer
    51 care
    52 choice
    53 clinical questions
    54 clinicians
    55 combination
    56 comprehensive guide
    57 crisis
    58 current article
    59 cyclin-dependent kinase 4/6 inhibitors
    60 decisions
    61 disease
    62 endocrine resistance
    63 endocrine therapy
    64 epidermal growth factor receptor
    65 evidence-based answers
    66 expert group meeting
    67 factor receptor
    68 factors
    69 first-line standard
    70 group meetings
    71 growth factor receptor
    72 guide
    73 hormone
    74 hr
    75 human epidermal growth factor receptor
    76 influence
    77 inhibitors
    78 initial treatment choice
    79 introduction
    80 key clinical questions
    81 key opinion leaders
    82 landscape
    83 leaders
    84 literature
    85 maintenance regimen
    86 management
    87 management of HR
    88 meeting
    89 metastatic breast cancer
    90 need
    91 oligometastatic disease
    92 opinion leaders
    93 optimal maintenance regimen
    94 optimized care
    95 ovarian function suppression
    96 panel
    97 partners
    98 patients
    99 policy
    100 purpose
    101 questions
    102 receptors
    103 regimen
    104 regional policy
    105 registry
    106 resistance
    107 review
    108 role
    109 scenarios
    110 second-line treatment
    111 selection
    112 sequencing
    113 sequencing decisions
    114 standards
    115 suppression
    116 therapeutic landscape
    117 therapy
    118 therapy choice
    119 treatment
    120 treatment choice
    121 treatment selection
    122 unmet need
    123 visceral crisis
    124 schema:name Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting
    125 schema:pagination 15
    126 schema:productId N88e515ed361f4a939b56d48abacdbd59
    127 Nb807017f573248f880e0561a427f485a
    128 Nd7fb05ea328d489989a3944298f52e3a
    129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140286771
    130 https://doi.org/10.1186/s12919-021-00224-5
    131 schema:sdDatePublished 2022-06-01T22:25
    132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    133 schema:sdPublisher Nbaa0b4c224d3408187cc1d5a88355ec6
    134 schema:url https://doi.org/10.1186/s12919-021-00224-5
    135 sgo:license sg:explorer/license/
    136 sgo:sdDataset articles
    137 rdf:type schema:ScholarlyArticle
    138 N0e96d729f3244b959eb25c41ffce7bab schema:volumeNumber 15
    139 rdf:type schema:PublicationVolume
    140 N10755aad87184d19bc8da27c6797f09f rdf:first sg:person.01361171050.45
    141 rdf:rest N50e7f821c00d426398dc4d6bd272f264
    142 N50e7f821c00d426398dc4d6bd272f264 rdf:first sg:person.01057754421.80
    143 rdf:rest Nec58ac480d5b463abc3fff9fa42161a6
    144 N68da39c50dd344cc9a8f00652e44bf4b rdf:first sg:person.0751031116.18
    145 rdf:rest N817e721f39dd49d0b453ebb2d6ec3b92
    146 N8120ca377cd447d6b22d9f6db7939f43 rdf:first sg:person.0771637610.47
    147 rdf:rest Nb879a074813248f283cb050f618afa4e
    148 N817e721f39dd49d0b453ebb2d6ec3b92 rdf:first sg:person.014520232162.61
    149 rdf:rest rdf:nil
    150 N85de622219f54140816db3bf7d22ddf2 rdf:first sg:person.01057225306.39
    151 rdf:rest Nfa9df333c8f24c2db00f0fc230aefbb1
    152 N88e515ed361f4a939b56d48abacdbd59 schema:name doi
    153 schema:value 10.1186/s12919-021-00224-5
    154 rdf:type schema:PropertyValue
    155 Nb58e4c7906a84796bbe7f63b2bb8dcc0 schema:issueNumber Suppl 10
    156 rdf:type schema:PublicationIssue
    157 Nb807017f573248f880e0561a427f485a schema:name pubmed_id
    158 schema:value 34372853
    159 rdf:type schema:PropertyValue
    160 Nb879a074813248f283cb050f618afa4e rdf:first Nc4f2b1376f684bcf93da3beb60b0b0a6
    161 rdf:rest N10755aad87184d19bc8da27c6797f09f
    162 Nbaa0b4c224d3408187cc1d5a88355ec6 schema:name Springer Nature - SN SciGraph project
    163 rdf:type schema:Organization
    164 Nc4f2b1376f684bcf93da3beb60b0b0a6 schema:affiliation grid-institutes:grid.467082.f
    165 schema:familyName Konstantionva
    166 schema:givenName Maria
    167 rdf:type schema:Person
    168 Nd7fb05ea328d489989a3944298f52e3a schema:name dimensions_id
    169 schema:value pub.1140286771
    170 rdf:type schema:PropertyValue
    171 Nec58ac480d5b463abc3fff9fa42161a6 rdf:first sg:person.015757640033.05
    172 rdf:rest N85de622219f54140816db3bf7d22ddf2
    173 Nfa9df333c8f24c2db00f0fc230aefbb1 rdf:first sg:person.010052147233.95
    174 rdf:rest N68da39c50dd344cc9a8f00652e44bf4b
    175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Medical and Health Sciences
    177 rdf:type schema:DefinedTerm
    178 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    179 schema:name Oncology and Carcinogenesis
    180 rdf:type schema:DefinedTerm
    181 sg:journal.1039047 schema:issn 1753-6561
    182 schema:name BMC Proceedings
    183 schema:publisher Springer Nature
    184 rdf:type schema:Periodical
    185 sg:person.010052147233.95 schema:affiliation grid-institutes:None
    186 schema:familyName Franco
    187 schema:givenName Sandra
    188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010052147233.95
    189 rdf:type schema:Person
    190 sg:person.01057225306.39 schema:affiliation grid-institutes:grid.419167.c
    191 schema:familyName Villarreal-Garza
    192 schema:givenName Cynthia
    193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057225306.39
    194 rdf:type schema:Person
    195 sg:person.01057754421.80 schema:affiliation grid-institutes:grid.418248.3
    196 schema:familyName Perazzo
    197 schema:givenName Florencia
    198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057754421.80
    199 rdf:type schema:Person
    200 sg:person.01361171050.45 schema:affiliation grid-institutes:grid.410724.4
    201 schema:familyName Dent
    202 schema:givenName Rebecca
    203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361171050.45
    204 rdf:type schema:Person
    205 sg:person.014520232162.61 schema:affiliation grid-institutes:None
    206 schema:familyName Simon
    207 schema:givenName Sergio
    208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014520232162.61
    209 rdf:type schema:Person
    210 sg:person.015757640033.05 schema:affiliation grid-institutes:grid.413967.e
    211 schema:familyName Kim
    212 schema:givenName Sung-Bae
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015757640033.05
    214 rdf:type schema:Person
    215 sg:person.0751031116.18 schema:affiliation grid-institutes:grid.278244.f
    216 schema:familyName Dai
    217 schema:givenName Ming-Shen
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751031116.18
    219 rdf:type schema:Person
    220 sg:person.0771637610.47 schema:affiliation grid-institutes:grid.459770.8
    221 schema:familyName Dawood
    222 schema:givenName Shaheenah
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771637610.47
    224 rdf:type schema:Person
    225 sg:pub.10.1007/s10549-013-2814-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041934981
    226 https://doi.org/10.1007/s10549-013-2814-5
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.1007/s10549-017-4518-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092841000
    229 https://doi.org/10.1007/s10549-017-4518-8
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1007/s10549-017-4523-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1092334133
    232 https://doi.org/10.1007/s10549-017-4523-y
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1007/s10549-018-05125-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111320245
    235 https://doi.org/10.1007/s10549-018-05125-4
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1007/s10549-018-4867-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1105296572
    238 https://doi.org/10.1007/s10549-018-4867-y
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1007/s12282-012-0430-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032224793
    241 https://doi.org/10.1007/s12282-012-0430-6
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1007/s12282-018-0838-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101057009
    244 https://doi.org/10.1007/s12282-018-0838-8
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1007/s12325-013-0060-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016141409
    247 https://doi.org/10.1007/s12325-013-0060-1
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1038/s41523-018-0094-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110537179
    250 https://doi.org/10.1038/s41523-018-0094-2
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/s41523-018-0097-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1111375485
    253 https://doi.org/10.1038/s41523-018-0097-z
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1186/s12885-020-06933-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1127579844
    256 https://doi.org/10.1186/s12885-020-06933-y
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1186/s12916-019-1326-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114002245
    259 https://doi.org/10.1186/s12916-019-1326-5
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1186/s13045-018-0620-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104512198
    262 https://doi.org/10.1186/s13045-018-0620-6
    263 rdf:type schema:CreativeWork
    264 grid-institutes:None schema:alternateName Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil
    265 Head of Oncology, Clínica del Country, Bogotá, Colombia
    266 schema:name Centro Paulista de Oncologia (CPO), Sao Paulo, Brazil
    267 Head of Oncology, Clínica del Country, Bogotá, Colombia
    268 rdf:type schema:Organization
    269 grid-institutes:grid.278244.f schema:alternateName Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan
    270 schema:name Department of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei City, Taiwan
    271 rdf:type schema:Organization
    272 grid-institutes:grid.410724.4 schema:alternateName Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore
    273 schema:name Head, Breast Medical Oncology Team, National Cancer Center Singapore, Singapore, Singapore
    274 rdf:type schema:Organization
    275 grid-institutes:grid.413967.e schema:alternateName Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea
    276 schema:name Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, South Korea
    277 rdf:type schema:Organization
    278 grid-institutes:grid.418248.3 schema:alternateName Department of Oncology, Centro de Educación Médicae Investigaciones Clínicas (CEMIC), Ciudad de Buenos Aires, Argentina
    279 schema:name Department of Oncology, Centro de Educación Médicae Investigaciones Clínicas (CEMIC), Ciudad de Buenos Aires, Argentina
    280 rdf:type schema:Organization
    281 grid-institutes:grid.419167.c schema:alternateName Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico
    282 schema:name Centro de Cancer de Mama, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza García, NL, Mexico
    283 Depto. de Investigacion, Instituto Nacional de Cancerologia, Mexico city, Mexico
    284 rdf:type schema:Organization
    285 grid-institutes:grid.459770.8 schema:alternateName Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE
    286 schema:name Dubai Health Care City, Consultant Medical Oncologist, Mediclinic City Hospital - North Wing, Dubai, UAE
    287 rdf:type schema:Organization
    288 grid-institutes:grid.467082.f schema:alternateName Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia
    289 schema:name Head of the Department of antitumor drug therapy, F. VladimirskIy Moscow Regional Research Clinical Institute (MONIKI), Moscow, Russia
    290 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...